Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Depreivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Enzalutamide (Primary) ; Bicalutamide; Gonadotropin releasing hormone
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 Apr 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2018.
- 03 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Dec 2018.